Home
About
Company Profile
Corporate Culture
Team
Group structure
Investor relations
Business
News
Group dynamics
Media report
Technical article
Recruitment
Contact
Contact
Message
EN
EN
CN
Taichu Biotechnology
Innovative Drug Non Clinical Research and Service Platform (CRO)
AceMab
AceMouse ™- The most perfect antibody fully humanized mouse platform (CRO)
Tayzen
Pharmaceutical Preparation Process Development and Production Service Platform (CDMO)
Tarlead
Antibody drug process development and production service platform (CDMO)
TJR BIO
End-to-end Service from Oligonucleotide R&D to drug product manufacturing (CDMO)
Taichu (Shenzhen)
Consulting Services&Business Activities
Home
About
Company Profile
Corporate Culture
Team
Group structure
Investor relations
Business
Taichu Biotechnology
AceMab
Tayzen
Tarlead
TJR BIO
Taichu (Shenzhen)
News
Group dynamics
Media report
Technical article
Recruitment
Contact
Contact
Message
News information
The latest information of Taichu Group is all here
Group dynamics
Media report
Technical article
Home
>
News
>
Group dynamics
Year
All
2023
2022
2021
Search
Talking about the Structure Characterization of Antibody Drugs
The development, application, and production process of antibody drugs are accompanied by quality research and control of products. The quality analysis of antibody drugs involves multiple aspects, and both the European Medicines Agency (EMA) and the International Conference on Harmonization (ICH) guidelines Q6B [1,2] require characterization of antibody drugs
04-10
2023
ADA Discussion: Immunogenicity of Therapeutic Antibodies
In 1890, German physiologist Emil von Behring and Japanese microbiologist Shibasaburo Kitasato found a substance that can neutralize the toxin in the blood of animals exposed to Diphtheria toxin and tetanus toxin, and named it Antibody.
04-06
2023
Taijin Biotechnology and Jinyu Bowo Runze announced a strategic partnership to assist in the development of therapeutic all human dual antibody drugs
On March 28, 2023, Shanghai Taijin Biotechnology Co., Ltd. (referred to as Taijin Biotechnology) and Jinyu Bowo Runze Biotechnology Co., Ltd. (referred to as Jinyu Biotechnology) announced a strategic partnership, jointly committed to the development of therapeutic all human dual antibody drugs.
03-28
2023
German Vetter Company Visits Taili Biotech Suzhou Factory
Suzhou, March 16, 2023. Mr. Oskar Gold, Senior Vice President of Asia Pacific and Global Emerging Markets at Vetter Fiat, and Mr. Daniel Zhang, Head of Marketing in China, visited Tai Li Bio's Suzhou factory.
03-16
2023
Taichu Group will appear at the upcoming 2023 SOT exhibition
The 62nd Annual American Toxicology Conference will be held from March 19th to 23rd in Nashville, Tennessee, USA. The mission of the American Society of Toxicology (SOT) is to promote the acquisition and application of toxicology knowledge, and to facilitate information exchange between other members and other disciplines.
03-13
2023
Chongde Seeks Truth, Achieves Customers | Taichu Biological's Non Clinical Safety Evaluation Business Section Officially Launches GLP Operation
Shanghai Taichu Biotechnology Co., Ltd. (Taichu Biotechnology) has undergone preliminary preparation and various preparations for the non clinical safety evaluation section of drugs. Starting from March 1, 2023, the trial operation will be fully carried out in accordance with the Good Clinical Practice (GLP) for drug non clinical research.
03-08
2023
How can B cells achieve both fish and bear paws with high affinity and diversity?
It is no exaggeration to say that bacteria and viruses are the most threatening thing to humanity, the most formidable opponent, and the most likely thing to cause human extinction. From the "Black Death" of the past to the "COVID-19" of the present, mankind was caught off guard. The Black Death was caused by the pestis, and the pathogenic bacteria were mainly bacteria. In the middle of the 14th century, the population of Europe was reduced by 40% - 60%.
03-07
2023
<
1
2
>
Prev
1/2
Next